An observational study in Influenza Viruses, Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.
Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.
The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.
Patients aged >65 years with a diagnosis of acute respiratory infection and hospitalized in acute/geriatric wards
Exclusion Criteria:
Patients aged 65 years or older hospitalized in acute medicine or geriatric wards with an acute respiratory infection and a positive nasopharyngeal PCR test for a respiratory viral pathogen.
Other: Respiratory viral infection
Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.
Proportion of participants with death and/or organ decompensation at Day 180
Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.
Time frame: From baseline Day 0 to Day 180
Proportion of participants who died
Proportion of participants who died from any cause during follow-up.
Time frame: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants with major organ decompensation
Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation.
Time frame: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants with unplanned hospital readmission
Proportion of participants experiencing an unplanned hospital readmission during follow-up.
Time frame: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants developing a lower respiratory tract infection
Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection.
Time frame: From baseline Day 0 to Day 30
Change from baseline in functional dependency assessed by ADL and/or iADL scores
Change in functional dependency from baseline, assessed using the Activities of Daily Living (ADL) and/or Instrumental Activities of Daily Living (iADL) scores.
Time frame: Baseline Day 0, Day 30, Day 180, Day 365
Change from baseline in sarcopenia risk assessed by SARC-F score
Change in sarcopenia risk from baseline, assessed using the SARC-F score.
Time frame: Baseline Day 0, Day 30, Day 180, Day 365
Change from baseline in quality of life assessed by EQ-5D-3L
Change in health-related quality of life from baseline, assessed using the EQ-5D-3L questionnaire.
Time frame: Baseline Day 0, Day 30, Day 180, Day 365
Number and type of bacterial and viral co-infections
Number and type of bacterial and viral co-infections diagnosed at the same time as, or within seven days following, the occurrence of the first respiratory viral infection.
Time frame: Baseline Day 0 to D7
Change in respiratory viral load between Day 0 and Day 7
Change in viral load between Day 0 and Day 7 for each respiratory virus identified in study participants.
Time frame: From Day 0 to Day 7
Proportion of participants with death and/or major organ decompensation at Day 30
Proportion of participants who died and/or experienced major organ decompensation by Day 30. This outcome will be used to assess vaccine effectiveness for vaccine-preventable respiratory viral infections.
Time frame: From baseline Day 0 to Day 30
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris